JCI Insight: New Discovery! Identify new checkpoints for colorectal cancer immunotherapy!

2020 May 17 News /BioValleyBIOON / - Recently, research onJCIInsightan international journal published report scientists from Indiana University School of Medicine and other institutions through research identified new targets of colorectal cancer immunotherapy; immunotherapy can take advantage of the host body's own immune system to destroy targeted cancer cells, taking into account the future of cancer treatment , significantly less than the toxicity of chemotherapy, immunotherapy, colorectal cancer is the third most common type of cancer in the population, but due to the current therapies on the immune response of a limited number of patients with colorectal cancer, chemotherapy remains the standard therapy for the treatment of such cancersSource:medicalxpress.comthis study, researchers or are expected to provide a novel immunotherapy path to help treat patients with colorectal cancer , the researchers found, ST2 can be used as a new type of checkpoint molecules enable T cells to become more efficient; immune checkpoint is a key part of the immune system, which plays a key role in the prevention of immune cells destroy healthy cells, T cells can attack is an important immune cells such as cancer cells or infectious agents derived loaded with foreign substances, but cancer is cunning, usually, a tumor microenvironment may develop a new path to suppress T-cell misuse by a variety of factors (including checkpoint activation molecules, etc.) to attack cancer cellsin the tumor microenvironment, the immune system to know which part of the error, it sends an alert element such as IL-33 and other pressure signals, it will be introduced into the macrophages express ST2 (IL-22 in receptors) to help better to start a rapid reaction will be dumb film, so it will become macrophages against enemies of colorectal cancertumor patient using genetic researchersdata analysis found that the body, decreased levels of T cells occur in patients with elevated ST2 levels, and cancer using tissueafter the tumor tissue sample is a biological sample library study, researchers found early advanced colorectal cancer to a high level of ST2tumor tissue sample macrophagesVanderJeught researchers said, in all patient samples, researchers have identified the macrophages express ST2, which means that potential, targeting these ST2 macrophages or with the patient treatment-related, in preclinical mouse models, researchers say, ST2 expressing macrophages by targeting, they can slow the growth of tumors, and by eliminating these suppressor cells, T cells will be more active against cancerresearchers are currently using the current immunotherapy (such as PD-1 checkpoint inhibitor therapy) to develop a novel combination therapy, which can enhance T cell activity directly, by blocking while also inhibiting functional agent to attack the macrophages to increase the level of ST2 in T cells Exert different effects on the immune system by using two potential checkpoint inhibitors, researchers may enhance the reaction rate is expected to patients with colorectal cancer Next the researchers plan based on the results of this in-depth research to develop ST2 based cancer immunotherapy (Biovalley Bioon.com) Original source: KevinVanderJeught, YifanSun, YuanzhangFang, etal ST2ascheckpointtargetforcolorectalcancerimmunotherapy , JCIInsight < br /> (2020) .DOI: 10.1172 / jci.insight.136073